Study clarifies best treatments for uncommon kidney cancers
the ONA take:
Researchers at Duke Cancer Institute led a study comparing two biologic therapies used to treat a subset of advanced kidney cancers.
The head-to-head comparison offers clinicians much-needed clarity on the preferred first-line treatment of these cancers.
The study focused on three form of non-clear cell kidney cancers: metastatic papillary, chromophobe, or unclassified. In the study, 108 patients were randomly assigned to receive either everolimus or sunitinib, the two treatments approved for these cancers, until their tumors progressed.
The findings show that sunitinib was superior overall at prolonging the time to tumor regrowth, but at a higher rate of severe toxicity.
Sunitinib was also more effective for papillary-type kidney cancers and for better prognosis patients. Everolimus offered longer median progression-free survival for patients with chromophobe and poor-risk tumors.
In addition, more than 100 study participants donated tumor tissue. The researchers now have the largest repository of non-clear cell kidney cancer tissue to aid in further research toward developing new drugs and identifying biomarkers for the disease.
Head-to-head comparison offers clinicians much-needed clarity on the preferred first-line treatment of kidney cancers.
Sign Up for Free e-newsletters
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Depression Predictive of Poor Survival Outcomes in Head and Neck Cancer
- Nearly One Third of Veterans Report Current Tobacco Use
- Priority Review of New Drug Application Granted to Apalutamide for CRPC
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
- Novel Approach Can Improve Both Colorectal Cancer Screening Outcomes and Adherence
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|